Common Antibiotic May Lower Risk of Schizophrenia

A large Finnish study finds that adolescents treated with the antibiotic doxycycline were significantly less likely to develop schizophrenia later, hinting at new preventive possibilities for severe mental illness.

Could a drug prescribed for acne quietly protect against schizophrenia? A new study led by the University of Edinburgh, published in the American Journal of Psychiatry, suggests it might.
Researchers found that adolescents who received the antibiotic doxycycline were up to 35% less likely to develop schizophrenia in adulthood compared with peers who took other antibiotics(1^✔ ✔Trusted Source
Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial

Go to source

).
The finding offers a striking possibility that an existing, affordable drug might one day help prevent one of psychiatry’s most devastating disorders.

Inside the Study

The team, working with colleagues from Finland’s University of Oulu and University College Dublin, analyzed healthcare data from more than 56,000 adolescents who attended mental-health services between 2006 and 2020.

Using national prescription and diagnostic records, they compared teens who were prescribed doxycycline against those who received other antibiotics. Even after adjusting for confounders such as infection type or acne treatment, the doxycycline group showed a 30–35% reduced risk of later schizophrenia diagnosis.

Why Might an Antibiotic Protect the Brain?

Doxycycline, part of the tetracycline family, is widely used to treat acne and infections, but it also has powerful anti-inflammatory and neuroprotective properties.

In brain research, doxycycline is known to:

• Reduce inflammation in microglial cells, the brain’s immune system.
• Influence synaptic pruning, the process that refines neural connections during adolescence. Excessive pruning, when the brain trims away too many synapses, has long been linked to schizophrenia risk.

Study authors propose that doxycycline may help balance this pruning process and dampen neuroinflammatory pathways that contribute to the disorder’s onset.

Expert Insight

Professor Ian Kelleher, lead investigator and Professor of Child and Adolescent Psychiatry at the University of Edinburgh, said: “As many as half of the people who develop schizophrenia had previously attended child and adolescent mental health services. At present, we have no interventions that are known to reduce that risk. This makes our findings very exciting.”

However, he also stressed caution: “Because this study was observational, we can’t yet prove causality. But the results are a strong signal that deserves urgent follow-up.”

Broader Implications

Schizophrenia affects about 1 in 100 people worldwide, typically emerging in late adolescence or early adulthood. It carries profound personal and societal costs, from lifelong disability to social stigma and reduced life expectancy.

If doxycycline or similar anti-inflammatory drugs can lower risk in vulnerable youth, it could represent a transformative step in preventive psychiatry.

Still, researchers emphasize that this is not a call to prescribe antibiotics routinely. Large-scale randomized trials will be needed to confirm whether doxycycline truly offers protective effects.

Final Takeaway

The study adds weight to a growing theory: brain inflammation plays a key role in severe mental illness. Doxycycline’s apparent protective link opens a door to new prevention strategies, not through new drugs, but by re-examining those we already have.

For now, scientists are cautious but optimistic. What began as an acne treatment could someday inform how we protect young minds from schizophrenia’s reach.

Reference:

1. Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial – (https://psychiatryonline.org/doi/10.1176/appi.ajp.20240958)

Source-Medindia